

Please try another search
NovoCure Limited is a global oncology company, which is principally engaged in the development, manufacturing and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields therapy has applicability across solid tumor types and lines of therapy. It is conducting phase three pivotal studies evaluating the use of TTFields in non-small cell lung cancer (NSCLC), ovarian cancer, brain metastases from NSCLC, and pancreatic cancer. The Company’s key priorities are to drive commercial adoption of Optune and Optune Lua, its commercial TTFields devices. The Company markets Optune in the United States, Germany, Japan and other countries. The Company markets Optune Lua in the United States and European Union. It also has a licence to market Optune in China, Hong Kong, Macau and Taiwan.
Name | Age | Since | Title |
---|---|---|---|
William F. Doyle | 59 | 2004 | Executive Chairman |
Asaf Danziger | 55 | 2002 | President, CEO & Director |
William Anthony Vernon | 66 | 2006 | Lead Independent Director |
Kinyip Gabriel Leung | 60 | 2011 | Independent Director |
Jeryl Lynn Hilleman | 64 | 2018 | Independent Director |
Martin J. Madden | 61 | 2017 | Independent Director |
David T. Hung | 64 | 2018 | Independent Director |
Timothy John Scannell | 57 | 2021 | Independent Director |
Allyson J. Ocean | 51 | 2023 | Independent Director |
Kristin Stafford | 41 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review